Home » Judge Rejects Motion to Dismiss BMS Patent Case
Judge Rejects Motion to Dismiss BMS Patent Case
A district court has denied a motion by Mylan Pharmaceuticals
and its unit Matrix Laboratories to dismiss a patent infringement lawsuit
by Bristol-Myers Squibb (BMS) over its HIV drug Sustiva. BMS sued Matrix and Mylan in the U.S. District Court for the District of Delaware for infringing
its ‘372 patent by filing an ANDA for a generic form of Sustiva (efavirenz) tablets. The patent expires in 2012.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May